[The kidney in children under chemotherapy].
Nowadays more and more children survive after an intensive anti-tumoral therapy. The price to pay consists of numerous and relatively frequent long-term sequelae (secondary tumors, neuropsychological deficits, endocrine or cardiac damage). After chemotherapy, we sometimes observe renal side-effects, either tubular (metabolic acidosis, hypokalemia, hypomagnesemia, proteinuria, Fanconi syndrome, rickets) or glomerular (acute or chronic decreased GFR). These renal toxic side-effects are encountered especially after cisplatinum and ifosfamide, less frequently after carboplatin and cyclophosphamide. The pediatrician has to be aware of these toxic nephrologic side-effects, to look out for them and monitor carefully the renal function of all paediatric patients receiving these potentially nephrotoxic chemotherapies.
Cachat
F
F
Service de pédiatrie, CHUV, Lausanne.
Guignard
J P
JP
D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000633:toxicity; D018906:Antineoplastic Agents, Alkylating / Q000009:adverse effects; D016190:Carboplatin / Q000009:adverse effects; D002648:Child; D002945:Cisplatin / Q000009:adverse effects; D005919:Glomerular Filtration Rate / Q000187:drug effects; D006801:Humans; D007069:Ifosfamide / Q000009:adverse effects; D007668:Kidney / Q000187:drug effects*; D007674:Kidney Diseases / Q000139:chemically induced / Q000175:diagnosis; D007677:Kidney Function Tests; D008727:Methotrexate / Q000009:adverse effects; D016685:Mitomycin / Q000009:adverse effects; D012673:Semustine / Q000009:adverse effects
D000970:Antineoplastic Agents; D018906:Antineoplastic Agents, Alkylating; D012673:Semustine; D016685:Mitomycin; D016190:Carboplatin; D002945:Cisplatin; D007069:Ifosfamide; D008727:Methotrexate